Immunome, Inc. · NASDAQ:IMNM
Immunome — Investor Presentation (March 2021)
29 slides from Immunome's investor presentation, Mar 16, 2021
Slide 1: Harnessing the Human Memory B Cell Response To Develop Antibody-Based Therapeutics
Copyright © 2021 Immunome, Inc. All rights reserved. Harnessing the Human Memory B Cell Response To Develop Antibody - Based Therapeutics Immunome, Inc. 665 Stockton Drive, Suite 300 Exton, PA 19341 610.321.3700 www.immunome.com March 14, 2021
Slide 2: Forward-looking statements
Copyright © 2021 Immunome, Inc. All rights reserved. This presentation and any accompanying oral commentary contain “forward - looking statements” within the meaning of the Private Se curities Litigation Reform Act of 1995. All statements other than those of historical fact in this presentation and
Slide 3: Immunome Overview
Copyright © 2021 Immunome, Inc. All rights reserved. Proprietary Discovery Engine • Rapid and unbiased interrogation of memory B cells to identify novel targets and antibodies directed at them • Output has potential to advance 1 - 2 candidates into IND - enabling studies per year • Broad applicabili
Slide 4: The Power of Memory B Cells
Copyright © 2021 Immunome, Inc. All rights reserved. The Power of Memory B Cells Immunome’s Discovery Engine Sees Disease Through the Lens of the Human Memory B Cell Immunome, Inc. | Page 4 Memory B cells are the most educated component of the immune response • Memory B cells remember specific antig
Slide 5: Immunome Discovery Engine
Copyright © 2021 Immunome, Inc. All rights reserved. Immunome Discovery Engine Unbiased Interrogation of Memory B Cells Yields a Deep and Diverse Set of Potential Therapies Immunome, Inc. | Page 5 Immunome Discovery Engine Differentiators • Primary human memory B cells immortalized as stable hybrido
Slide 6: Immunome Pipeline & Anticipated Milestones
Copyright © 2021 Immunome, Inc. All rights reserved. Immunome Pipeline & Anticipated Milestones Immunome, Inc. | Page 6 Oncology Target Product Candidate Description Discovery Preclinical Next Milestone IMM - ONC - 01 IL - 38 I/O, Novel Checkpoint Anticipate IND filing 2H 2021 Anti - infectives Targ
Slide 7: Oncology
Copyright © 2021 Immunome, Inc. All rights reserved. Oncology
Slide 8: Untapped Potential in Immuno-Oncology
Copyright © 2021 Immunome, Inc. All rights reserved. Current Therapies are Based on Limited Understanding of the Diversity and Complexity of Human Tumors Immunome, Inc. | Page 8 T cell targeted immuno - oncology approaches have redefined the way we treat cancer However, large number of patients cann
Slide 9: Immunome's Discovery & Output
Copyright © 2021 Immunome, Inc. All rights reserved. Immunome’s Discovery & Output Memory B Cell Interrogation Reveals Target “Clusters” Immunome, Inc. | Page 9 1. Adv Clin Chem. 2016;74:103 - 41.DOI: 10.1016/bs.acc.2015.12.005 2. Mol Cancer. 2019 Oct 23;18(1):146. doi: 10.1186/s12943 - 019 - 1074 -
Slide 10: IL-38: A Novel Oncology Target
Copyright © 2021 Immunome, Inc. All rights reserved. IL - 38: A Novel Oncology Target IL - 38 Appears to Dampen Anti - Tumor Immunity Immunome, Inc. | Page 10 Blocking IL - 38 is expected to boost anti - tumor immunity • IL - 38 is an IL - 1 cytokine family member, but most closely resembles the nat
Slide 11: IL-38 Expression in Solid Tumors
Copyright © 2021 Immunome, Inc. All rights reserved. Inverse relationship between IL - 38 expression and immune cell infiltration in tumors • IL - 38 expressed at high levels in subsets of biopsies of major solid tumors 1 • Biopsy material from 400 lung cancer patients revealed association between h
Slide 12: Relationship with Patient Outcomes
Copyright © 2021 Immunome, Inc. All rights reserved. Relationship with Patient Outcomes IL - 38 Levels Correlate with Poor Patient Outcomes Immunome, Inc. | Page 12 Low IL - 38 correlates with longer disease - free & overall survival in lung adenocarcinoma patients High IL - 38 expression correlates
Slide 13: IL-38 and Innate Immunity
Copyright © 2021 Immunome, Inc. All rights reserved. IL - 38 and Innate Immunity IL - 38 Inhibits Myeloid Cell Activation In Vitro Immunome, Inc. | Page 13 Blocks IL - 36 mediated inflammatory signals Inhibits macrophage inflammatory response LPS induced RNA expression in THP - 1 Immunome Data IL -
Slide 14: IL-38 Antibody In Vivo Efficacy
Copyright © 2021 Immunome, Inc. All rights reserved. IL - 38 Antibody In Vivo Efficacy IMM - ONC - 01 Inhibits Tumor Growth in Animal Model Immunome, Inc. | Page 14 • B16 F10 mouse melanoma model: immunologically cold • Expresses IL - 38: Immune - suppressive tumor microenvironment • Mouse CTLA4 inh
Slide 15: IMM-ONC-01 Program Summary
Copyright © 2021 Immunome, Inc. All rights reserved. IMM - ONC - 01 Program Summary Immunome, Inc. | Page 15 Modulating Innate Anti - Tumor Immunity IMM - ONC - 01 is a first - in - class, fully - human antibody candidate targeting IL - 38 • IL - 38 regulates adaptive and innate immunity by binding
Slide 16: Infectious Diseases
Copyright © 2021 Immunome, Inc. All rights reserved. Infectious Diseases
Slide 17: Therapeutic Antibody Cocktail Against Multiple SARS-CoV-2 Antigens
Copyright © 2021 Immunome, Inc. All rights reserved. Therapeutic Antibody Cocktail Against Multiple SARS - CoV - 2 Antigens Immunome, Inc. | Page 17 IMM - BCP - 01 Collaboration with U.S. DoD awarded, up to $13.3M in funding Select convalescent patients with strong anti - viral titer Antibody cockta
Slide 18: IMM-BCP-01 Hypothesis
Copyright © 2021 Immunome, Inc. All rights reserved. IMM - BCP - 01 Hypothesis Other Single Neutralizing Antibody Therapeutics vs. Immunome’s Antibody Cocktail Approach Immunome, Inc. | Page 18 Single Neutralizing Antibody • Targets single protein • New strains may readily evade IMM - BCP - 01 Profi
Slide 19: B Cell Interrogation of Super-Responders
Copyright © 2021 Immunome, Inc. All rights reserved. B Cell Interrogation of Super - Responders Anti - SARS - CoV - 2 Antibodies from “Super Responders” Immunome, Inc. | Page 19 More than 50% of the antibodies identified bind to SARS - CoV - 2 proteins other than Spike https://www.biorxiv.org/conten
Slide 20: Anti-Spike Antibodies
Copyright © 2021 Immunome, Inc. All rights reserved. Anti - Spike Antibodies Super Responders Express Broadly Neutralizing Anti - Spike SARS - CoV - 2 Antibodies Immunome, Inc. | Page 20 https://www.biorxiv.org/content/10.1101/2021.01.27.428534v1). SARS - CoV2 super responders mount a robust immune
Slide 21: IMM-BCP-01 Program Summary
Copyright © 2021 Immunome, Inc. All rights reserved. IMM - BCP - 01 Program Summary Immunome, Inc. | Page 21 Antibody Cocktail Targeting the Multiple SARS - CoV - 2 Antigens IMM - BCP - 01: potential as therapy and prophylaxis for SARS - CoV - 2 • Immunome data confirm that patients mount immune res
Slide 22: Summary
Copyright © 2021 Immunome, Inc. All rights reserved. Summary
Slide 23: Immunome Pipeline & Anticipated Milestones
Copyright © 2021 Immunome, Inc. All rights reserved. Immunome Pipeline & Anticipated Milestones Immunome, Inc. | Page 23 Oncology Target Product Candidate Description Discovery Preclinical Next Milestone IMM - ONC - 01 IL - 38 I/O, Novel Checkpoint Anticipate IND filing 2H 2021 Anti - infectives Tar
Slide 24: Immunome summary
Copyright © 2021 Immunome, Inc. All rights reserved. Immunome Immunome, Inc. | Page 24 Harnessing the power of the most - educated components of the human immune system • Proprietary Discovery Engine enables the interrogation of human memory B cells to simultaneously identify potential first - in -
Slide 25: Appendix
Copyright © 2021 Immunome, Inc. All rights reserved. Appendix
Slide 26: Management Team
Copyright © 2021 Immunome, Inc. All rights reserved. Management Team Immunome, Inc. | Page 26 Michael Morin, PhD Chief Science Officer Oversaw cancer, immunology and anti - bacterial drug discovery Diane Marcou Chief Financial Officer Jillian DiMuzio Senior Director, HTS & Automation Ben Harman, PhD
Slide 27: Scientific Advisory Board
Copyright © 2021 Immunome, Inc. All rights reserved. Scott Dessain, MD, PhD Chair, Founder Joseph and Ray Gordon Chair of Clinical Oncology and Research at Lankenau Institute for Medical Research George Prendergast, PhD Cancer Biology Former Editor of Cancer Research President and CEO of Lankenau In
Slide 28: Board of Directors
Copyright © 2021 Immunome, Inc. All rights reserved. Michael Rapp Managing Partner, Broadband Capital Investments, LLC Richard Baron Formerly Chief Financial Officer, Zynerba Pharmaceuticals John LaMattina, PhD Formerly President, Pfizer Global Research & Development Michael Lefenfeld President and
Slide 29: Stockton Drive, Suite Exton, PA 19341 610.321.3700 www.immunome.com
Copyright © 2021 Immunome, Inc. All rights reserved. 665 Stockton Drive, Suite 300 Exton, PA 19341 610.321.3700 www.immunome.com